검색어: peripheral joint (영어 - 덴마크어)

peripheral joint
randfuge

peripheral
ydre enhed

peripheral,
Øjne

neuropathy peripheral
perifer neuropati

peripheral, peripheral
reaktioner på administrations - stedet

peripheral oedema§
perifert ødem§

vasodilators (peripheral)
vasodilatorer (periferale)

the slowing of peripheral joint damage was observed in patients with polyarticular symmetrical joint involvement.
den forsinkede skade på perifere led blev observeret hos patienter med polyartikulær, symmetrisk artrit.

· muscle weakness (possibly associated with peripheral neuropathy ­ see above) , joint pain,
· muskelsvaghed (muligvis i forbindelse med perifer neuropati ­ se ovenfor); ledsmerter,

thrombocytopenia, eosinophilia, pancytopenia and agranulocytosis, anemia, leucopenia. peripheral edema, palpitation and chest pain. muscle and joint pain
hepatitis, ikterus og interstitiel nefritis. thrombocytopeni, eosinofili, pancytopeni og agranulocytose, anæmi, leucopeni. perifert ødem, palpitationer og brystsmerter. muskel -og ledsmerter

83 function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease.
hos patienter med psoriasis artrit har enbrel vist sig at forbedre den fysiske funktion og at reducere udviklingen af perifere ledskader, målt ved hjælp af røntgen, hos patienter med polyartikulære, symmetriske undertyper af sygdommen.

ustekinumab has been shown to improve signs and symptoms, physical function and health-related quality of life, and reduce the rate of progression of peripheral joint damage in adult patients with active psa.
det er påvist, at ustekinumab forbedrer symptomerne, fysisk funktion og helbredsrelateret livskvalitet og reducerer progressionsraten for perifere ledskader hos voksne patienter med aktiv psa.

enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease.
hos patienter med psoriasisartrit har enbrel vist sig at forbedre den fysiske funktion og at reducere udviklingen af perifere ledskader, målt ved hjælp af røntgen, hos patienter med polyartikulære, symmetriske undertyper af sygdommen.

humira has been shown to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.
humira har vist sig at reducere den udviklingshastighed, hvormed de perifere led destrueres, bedømt ved måling med røntgen hos patienter med polyartikulære, symmetriske undertyper af sygdommen (se pkt.5. 1) , og at forbedre den fysiske funktion.

contraindicated remicade has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) .
methotrexat er kontraindiceret det er blevet påvist, at remicade fremmer fysisk funktion hos patienter med psoriasis arthritis samt reducerer udviklingshastigheden af perifere ledskader målt med røntgen hos patienter med polyartikulære symmetriske undertyper af sygdommen (se pkt.5. 1) .

diarrhoea, insomnia, dizziness, chest pain, allergic reactions, numbness, joint pain and back pain, asthenia, peripheral oedema, itching.
muskelsmerter, muskelsvaghed, diarré, søvnløshed, svimmelhed, brystsmerter, allergiske reaktioner, følelsesløshed, led -og rygsmerter, kraftesløshed, perifert ødem, kløe.

peripherals
periferiudstyr